Dr. Campbell on the Future of the Management of RCC

Steven Campbell, MD, PhD
Published: Thursday, Aug 24, 2017



Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

In the future, researchers hope to see an increased utilization of partial nephrectomy and a more sensible utilization of radical nephrectomy, states Campbell.

Many are advocating for a utility-based approach to renal mass biopsy, meaning it will only be applied to patients who might have their treatment management changed, explains Campbell.



Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

In the future, researchers hope to see an increased utilization of partial nephrectomy and a more sensible utilization of radical nephrectomy, states Campbell.

Many are advocating for a utility-based approach to renal mass biopsy, meaning it will only be applied to patients who might have their treatment management changed, explains Campbell.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x